Baseline demographics and disease characteristics
| Parameter, n (%) | RA | PsA | AS | AD | ||||
| UPA 15 mg QD N=3209 | ADA 40 mg EOW N=579 | MTX N=314 | UPA 15 mg QD N=907 | ADA 40 mg EOW N=429 | UPA 15 mg QD N=182 | UPA 15 mg QD N=1340 | UPA 30 mg QD N=1353 | |
| Age (years), mean (SD) | 54.3 (12.0) | 54.1 (11.7) | 53.3 (12.9) | 51.5 (12.1) | 51.4 (12.0) | 45.3 (12.5) | 31.9 (15.2) | 33.0 (16.0) |
| Age ≥65 years | 643 (20.0) | 106 (18.3) | 58 (18.5) | 129 (14.2) | 67 (15.6) | 11 (6.0) | 48 (3.6) | 68 (5.0) |
| Female sex | 2581 (80.4) | 470 (81.2) | 240 (76.4) | 478 (52.7) | 222 (51.7) | 53 (29.1) | 593 (44.3) | 591 (43.7) |
| BMI, mean (SD) | 29.1 (6.7) | 29.4 (7.1) | 28.0 (6.3) | 30.6 (6.9) | 30.7 (7.2) | 26.7 (5.0) | 25.7 (6.0) | 25.8 (5.6) |
| BMI ≥30 kg/m2 | 1200 (37.4) | 227 (39.2) | 97 (30.9) | 429 (47.3) | 209 (48.7) | 37 (20.3) | 252 (18.9) | 258 (19.2) |
| Time since diagnosis (years), mean (SD) | 8.5 (8.4) | 8.2 (8.0) | 2.6 (5.1) | 7.2 (7.8) | 5.9 (7.1) | 6.9 (8.9) | 20.5 (14.2) | 20.7 (14.8) |
| Disease activity | ||||||||
| CRP-based disease measure, mean (SD)* | 5.8 (1.0) | 5.9 (1.0) | 5.9 (1.0) | 57.5 (29.7) | 54.8 (29.5) | 3.6 (0.8) | N/A | N/A |
| EASI, mean (SD) | N/A | N/A | N/A | N/A | N/A | N/A | 29.4 (12.3) | 29.1 (11.9) |
| Concomitant therapies | ||||||||
| csDMARD(s) | 2548 (79.4) | 579 (100) | 0 | 642 (70.8) | 338 (78.8) | 28 (15.4) | N/A | N/A |
| MTX alone | 2180 (67.9) | 579 (100) | 0 | 518 (57.1) | 269 (62.7) | 5 (2.7) | N/A | N/A |
| csDMARD other than MTX | 198 (6.2) | 0 | 0 | 89 (9.8) | 54 (12.6) | 22 (12.1) | N/A | N/A |
| Corticosteroids | 1761 (54.9) | 350 (60.4) | 164 (52.2) | 134 (14.8) | 72 (16.8) | 13 (7.1) | N/A | N/A |
| Topical glucocorticoids | N/A | N/A | N/A | N/A | N/A | N/A | 434 (32.4) | 446 (33.0) |
| NSAIDs | 2034 (63.4) | 362 (62.5) | 223 (71.0) | 566 (62.4) | 279 (65.0) | 149 (81.9) | N/A | N/A |
| Aspirin | 269 (8.4) | 36 (6.2) | 24 (7.6) | 89 (9.8) | 27 (6.3) | 6 (3.3) | 24 (1.8) | 41 (3.0) |
| Statin use | 369 (11.5) | 55 (9.5) | 26 (8.3) | 123 (13.6) | 42 (9.8) | 5 (2.7) | 11 (0.8) | 9 (0.7) |
| Patient history | ||||||||
| HZ | 68 (2.1) | 12 (2.1) | 4 (1.3) | 27 (3.0) | 6 (1.4) | 6 (3.3) | 27 (2.0) | 41 (3.0) |
| HZ vaccination | 90 (2.8) | 15 (2.6) | 4 (1.3) | 35 (3.9) | 14 (3.3) | 4 (2.2) | 51 (3.8) | 64 (4.7) |
| VTE | 53 (1.7) | 9 (1.6) | 3 (1.0) | 23 (2.5) | 3 (0.7) | 1 (0.5) | 4 (0.3) | 6 (0.4) |
| Number of CV risk factors† | ||||||||
| 0 | 739 (23.0) | 133 (23.0) | 82 (26.1) | 150 (16.5) | 90 (21.0) | 36 (19.8) | 635 (47.4) | 697 (51.5) |
| 1 | 1073 (33.4) | 202 (34.9) | 105 (33.4) | 308 (34.0) | 140 (32.6) | 73 (40.1) | 486 (36.3) | 439 (32.4) |
| 2 | 883 (27.5) | 160 (27.6) | 82 (26.1) | 251 (27.7) | 118 (27.5) | 54 (29.7) | 173 (12.9) | 166 (12.3) |
| 3 | 394 (12.3) | 63 (10.9) | 36 (11.5) | 151 (16.6) | 56 (13.1) | 18 (9.9) | 38 (2.8) | 45 (3.3) |
| 4+ | 120 (3.7) | 21 (3.6) | 9 (2.9) | 47 (5.2) | 25 (5.8) | 1 (0.5) | 8 (0.6) | 6 (0.4) |
| Presence of any CV risk factor | 2470 (77.0) | 446 (77.0) | 232 (73.9) | 757 (83.5) | 339 (79.0) | 146 (80.2) | 705 (52.6) | 656 (48.5) |
| Prior CV event | 384 (12.0) | 62 (10.7) | 27 (8.6) | 116 (12.8) | 40 (9.3) | 19 (10.4) | 67 (5.0) | 70 (5.2) |
| History of hypertension | 1301 (40.5) | 252 (43.5) | 112 (35.7) | 403 (44.4) | 179 (41.7) | 35 (19.2) | 149 (11.1) | 123 (9.1) |
| Diabetes mellitus | 382 (11.9) | 61 (10.5) | 31 (9.9) | 122 (13.5) | 47 (11.0) | 8 (4.4) | 26 (1.9) | 27 (2.0) |
| Tobacco/nicotine use‡ | 1221 (38.0) | 199 (34.4) | 120 (38.2) | 385 (42.4) | 163 (38.0) | 100 (54.9) | 418 (31.2) | 418 (30.9) |
| Elevated LDL-C (≥3.36 mmol/L) | 869 (27.2) | 170 (29.4) | 86 (27.5) | 253 (28.7) | 121 (28.7) | 43 (23.8) | 197 (14.9) | 185 (14.0) |
| Lowered HDL-C (<1.034 mmol/L) | 354 (11.0) | 53 (9.2) | 39 (12.4) | 176 (19.6) | 95 (22.4) | 34 (18.7) | 178 (13.4) | 168 (12.5) |
*Measures of disease activity are as follows: RA, DAS28 (CRP); PsA, DAPSA; AS, ASDAS.
†CV risk factors include history of CV event, hypertension, diabetes mellitus, tobacco/nicotine use, elevated LDL-C, lowered HDL-C.
‡Includes current and former use.
AD, atopic dermatitis; ADA, adalimumab; AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BMI, body mass index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CV, cardiovascular; DAPSA, Disease Activity index for PSoriatic Arthritis; DAS28, Disease Activity Score in 28 Joints; EASI, Eczema Area and Severity Index; EOW, every other week; HDL-C, high-density lipoprotein cholesterol; HZ, herpes zoster; LDL-C, low-density lipoprotein cholesterol; MTX, methotrexate; N/A, not applicable; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; QD, once a day; RA, rheumatoid arthritis; UPA, upadacitinib; VTE, venous thromboembolism.